SILO PHARMA, INC. — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/84229597-8fb3-466d-ab62-8211852ad6b4/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-4.3M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-035576 |
| FY 2024 | $-4.7M | 2024-01-01 – 2024-12-31 | evidence 0001013762-25-004139 |
| FY 2023 | $-3.9M | 2023-01-01 – 2023-12-31 | evidence 0001213900-24-025615 |
| FY 2022 | $-3.6M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-022813 |
| FY 2021 | $-2.7M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-015521 |
| FY 2020 | $-2.2M | 2020-01-01 – 2020-12-31 | evidence 0001213900-22-015521 |
| FY 2019 | $-930.4k | 2019-01-01 – 2019-12-31 | evidence 0001213900-20-007000 |
| FY 2018 | $-594.2k | 2018-01-01 – 2018-12-31 | evidence 0001213900-19-005789 |
| FY 2017 | $-490.9k | 2017-01-01 – 2017-12-31 | evidence 0001213900-19-005789 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).